SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

  • Adam J. Bass
  • , Hideo Watanabe
  • , Craig H. Mermel
  • , Soyoung Yu
  • , Sven Perner
  • , Roel G. Verhaak
  • , So Young Kim
  • , Leslie Wardwell
  • , Pablo Tamayo
  • , Irit Gat-Viks
  • , Alex H. Ramos
  • , Michele S. Woo
  • , Barbara A. Weir
  • , Gad Getz
  • , Rameen Beroukhim
  • , Michael O'Kelly
  • , Amit Dutt
  • , Orit Rozenblatt-Rosen
  • , Piotr Dziunycz
  • , Justin Komisarof
  • Lucian R. Chirieac, Christopher J. Lafargue, Veit Scheble, Theresia Wilbertz, Changqing Ma, Shilpa Rao, Hiroshi Nakagawa, Douglas B. Stairs, Lin Lin, Thomas J. Giordano, Patrick Wagner, John D. Minna, Adi F. Gazdar, Chang Qi Zhu, Marcia S. Brose, Ivan Cecconello, Ulysses Ribeiro, Suely K. Marie, Olav Dahl, Ramesh A. Shivdasani, Ming Sound Tsao, Mark A. Rubin, Kwok K. Wong, Aviv Regev, William C. Hahn, David G. Beer, Anil K. Rustgi, Matthew Meyerson*
*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

835 Scopus citations

Abstract

Lineage-survival oncogenes are activated by somatic DNA alterations in cancers arising from the cell lineages in which these genes play a role in normal development. Here we show that a peak of genomic amplification on chromosome 3q26.33 found in squamous cell carcinomas (SCCs) of the lung and esophagus contains the transcription factor gene SOX2, which is mutated in hereditary human esophageal malformations, is necessary for normal esophageal squamous development, promotes differentiation and proliferation of basal tracheal cells and cooperates in induction of pluripotent stem cells. SOX2 expression is required for proliferation and anchorage-independent growth of lung and esophageal cell lines, as shown by RNA interference experiments. Furthermore, ectopic expression of SOX2 here cooperated with FOXE1 or FGFR2 to transform immortalized tracheobronchial epithelial cells. SOX2-driven tumors show expression of markers of both squamous differentiation and pluripotency. These characteristics identify SOX2 as a lineage-survival oncogene in lung and esophageal SCC.

Original languageEnglish
Pages (from-to)1238-1242
Number of pages5
JournalNature Genetics
Volume41
Issue number11
DOIs
StatePublished - Nov 2009
Externally publishedYes

Funding

FundersFunder number
Sara Thomas Monopoli Lung Cancer Research Fund
Seaman Corporation Fund for Lung Cancer Research
U.S. Department of Defense
NIH Office of the DirectorDP1OD003958
National Cancer InstituteK08CA134931, R33CA128625, P50CA90578, R01CA071606-12, R01CA109038, P01CA098101-05, P50CA70907
Genentech
American Society of Clinical Oncology
Israel National Road Safety Authority
KWF Kankerbestrijding

    Fingerprint

    Dive into the research topics of 'SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas'. Together they form a unique fingerprint.

    Cite this